M42, a healthcare company based in Abu Dhabi that uses technology, has purchased Diaverum, a leading global provider of renal care services, from Bridgepoint Group.
Diaverum is the third-largest dialysis service provider in the world and operates in 23 countries with over 13,000 employees and 440 clinics. Its management team is highly experienced and focused on improving patient outcomes and innovating in tech-enabled care delivery. Diaverum has a strong track record of providing critical care to around 39,000 chronic kidney disease patients. M42, formed by the merger of G42 Healthcare and Mubadala Health, is a global leader in tech-enabled healthcare that combines unique medical and data-centric technologies with advanced facilities to provide precise, patient-centric, and preventative care, according to WAM.
The acquisition of Diaverum expands M42’s global presence and enhances its renal care offering in the GCC. Diaverum has expertise in tech-enabled care, including patient-centric apps and the potential to use AI to provide data-driven clinical insights for chronic kidney disease patients. M42 will leverage its knowledge and expertise in AI, genomics, and tech-powered solutions to enhance Diaverum’s ability to provide life-saving renal care.
The acquisition of Diaverum significantly expands M42’s global geographic footprint, enabling it to introduce relevant healthcare services and health tech solutions in new markets while further enhancing its renal care offering in the GCC. Furthermore, Diaverum has particular strength in tech-enabled care. This includes patient-centric apps and the potential to leverage AI to provide data-driven clinical insights for patients with chronic kidney disease. M42 will use its deep knowledge and expertise in AI, genomics, and tech-powered solutions to advance Diaverum’s ability to deliver precise, life-saving renal care.
Hasan Jasem Al Nowais, Group Chief Executive Officer and Managing Director of M42, commented, “M42’s acquisition of Diaverum represents a major milestone in our global expansion strategy. Diaverum is an exceptional company providing vital treatments that enable patients suffering from chronic kidney disease to live fulfilling lives. Its pioneering digital care offering fully aligns with M42’s focus on leveraging advanced technological solutions to deliver precise, personalised patient care. I look forward to working with Diaverum’s management team to address the critical challenge that chronic kidney disease represents to countries’ healthcare services around the world.”
Dimitris Moulavasilis, CEO of Diaverum, added, “We are very excited to be a part of M42’s integrated global network. M42 is a perfect fit for Diaverum’s future, and this transaction will further strengthen our position as a global leader in renal care. Together, we will be able to drive international growth and continue transforming the industry through patient-centric digital innovations. I would especially like to thank all our employees who make a difference in our patient’s lives every single day. They have been and will remain integral to Diaverum’s success story.”
Between 8 and 10 percent of the world’s adult population have some form of kidney damage, and every year millions die prematurely of complications related to chronic kidney disease. Due to the underlying growth of lifestyle diseases, including diabetes, the need for dialysis services in Diaverum’s markets saw patient growth of 8 percent Compound Annual Growth Rate (CAGR) between 2012 and 2019, with a similar growth rate expected over the next decade. The transaction, which is subject to customary regulatory approvals, is expected to close later in 2023.
